Mission Statement, Vision, & Core Values (2026) of PeptiDream Inc.

PeptiDream Inc. (4587.T), founded in 2006 and headquartered in Tokyo, has built a reputation as one of Japan's leading biotech firms by leveraging its proprietary Peptide Discovery Platform System (PDPS) to rapidly generate diverse peptide libraries and by expanding into radiopharmaceuticals through the strategic acquisition of PDRadiopharma, all in pursuit of discovering the next generation of transformational medicines that can reshape treatment paradigms and deliver measurable value to patients worldwide while embedding a culture that prizes expertise, passion, humility and integrity.

PeptiDream Inc. (4587.T) - Intro

• Founded: 2006 (Tokyo, Japan)
• Ticker: 4587.T (Tokyo Stock Exchange)
• Core technology: Peptide Discovery Platform System (PDPS)
• Therapeutic focus: Non-standard peptides, radiopharmaceuticals, targeted modalities
• Strategic expansion: integration of radiopharmaceutical capabilities via PDRadiopharma

• Revolutionize drug discovery by developing the next generation of transformational medicines for a healthier tomorrow.
• Deliver measurable value to patients worldwide through innovation in peptide therapeutics and radiopharmaceuticals.

• To be a global leader in peptide-based modalities, creating high-value assets and partnerships that translate platform outputs into approved medicines and clinical innovations.
• To continuously expand the therapeutic reach of non-standard peptides across oncology, metabolic, CNS, and rare disease indications.

• Innovation - relentless improvement of PDPS and discovery workflows to generate chemically diverse, drug-like peptide candidates.
• Scientific rigor - data-driven decision making, reproducibility, and translational focus from discovery to clinic.
• Collaboration - partnering with global pharma, biotech, and academic centers to accelerate development and broaden impact.
• Patient-centeredity - aligning R&D priorities to unmet medical needs and delivering therapeutic value to patients worldwide.
• Integrity & sustainability - transparent governance, responsible resource allocation, and long-term value creation for stakeholders.

• Peptide Discovery Platform System (PDPS) - enables rapid generation and screening of chemically diverse peptide libraries incorporating non-standard amino acids, macrocycles, and constrained architectures to access difficult targets.
• Pipeline generation - PDPS drives multiple out-licensed discovery programs and internally progressed candidates across therapeutic areas, enabling milestone and royalty revenue streams.
• Radiopharmaceutical integration - acquisition/expansion of PDRadiopharma capabilities to develop targeted radioligands and imaging/theranostic assets, bridging discovery to clinical-stage radiopharma development.

• Platform-driven collaborations: multiple global pharma/biotech partnerships leveraging PDPS to create modality-optimized peptide assets.
• Revenue model: combination of discovery fees, research funding, milestone payments, and potential royalties upon commercialization.
• Investment in R&D: sustained reinvestment to expand PDPS chemistry space and translational capabilities (R&D is a dominant cost center to drive future clinical value).

PeptiDream Inc. (4587.T) - Overview

• Mission focus: identify peptide-based therapeutics with high target specificity, favorable drug-like properties, and translational potential to become transformational medicines.
• Technology lever: proprietary PDPS (Peptide Discovery Platform System) enabling rapid identification of high-diversity peptide ligands and optimization for therapeutic use.
• Strategic expansion: PDRadiopharma initiative to develop radiopharmaceuticals for oncology diagnostics and targeted radiotherapies, leveraging peptide targeting capabilities.
• Collaboration model: partner-led R&D and licensing with bio/pharma companies, academic institutions, and specialty radiopharma firms to accelerate clinical translation and global reach.

• PDPS platform: combinatorial peptide libraries coupled with high-throughput screening and chemical modification nodes (macrocyclization, noncanonical amino acids) to enhance stability and affinity.
• PDRadiopharma: conjugation and isotope-labeling expertise for PET/SPECT imaging agents and targeted radiotherapeutics using peptide vectors.
• Pipeline strategy: parallel discovery tracks-internal preclinical programs plus partnered discovery and option/license deals to de-risk development and monetize platform outputs.

• Scientific rigor - prioritize reproducible, mechanism-driven discovery and translational validation.
• Innovation - continuously advance PDPS chemistry and screening to access chemical space beyond conventional peptides.
• Collaboration - build equitable partnerships that combine PeptiDream's peptide expertise with partners' development and commercialization capabilities.
• Patient-centricity - prioritize programs with potential for high unmet medical need and meaningful clinical benefit.
• Integrity & compliance - operate within global regulatory, IP, and ethical standards across discovery and radiopharmaceutical activities.

• Value creation through partnerships: discovery deals with up-front payments, R&D milestones, and downstream royalties/licensing revenues.
• Portfolio de-risking: maintain mix of partnered programs (to generate near-to-midterm revenue) and internal assets (to capture higher long-term upside).
• Capital allocation: reinvest collaboration proceeds into platform enhancement (chemistry, screening throughput) and PDRadiopharma capabilities.

• Mission-driven discovery: PDPS and PDRadiopharma operationalize the mission to produce transformational medicines-by discovering high-value peptide ligands and converting them into therapeutic or radiopharmaceutical candidates.
• Vision to lead peptide drug discovery: combining platform scalability, diversified partnerships, and targeted internal programs to achieve leadership in peptide-based modalities globally.
• Measurement of success: pipeline progression (IND/CTA filings), partner licensing milestones, clinical proof-of-concept readouts, and sustained revenue from collaborative programs.

PeptiDream Inc. (4587.T) - Mission Statement

• Platform strength: PDPS capable of generating and screening libraries in excess of 10^12 unique macrocyclic peptide candidates.
• Research-first approach: sustained investment in medicinal chemistry, structural biology, and assay development to advance hit-to-lead and optimization.
• Partnership-driven model: collaboration and licensing with biopharma companies to accelerate translational progress and broaden therapeutic reach.

• Novel modalities: prioritize macrocyclic peptides for targets that are challenging for small molecules or biologics.
• Global collaboration: leverage partnerships across North America, Europe, and Asia to accelerate development and broaden market access.
• Translational impact: aim to move multiple programs into the clinic via internal progress and out-licensing to development partners.

• Platform-led discovery: continual enhancement of PDPS throughput and hit triage pipelines to increase lead quality and speed.
• Strategic partnering: negotiating deals that balance near-term non-dilutive revenue (upfronts, milestones) with long-term royalties and co-development returns.
• Scientific depth: recruiting and retaining cross-disciplinary teams (chemistry, structural biology, translational research) to move candidates toward IND-enabling studies.

• Scale discovery output while improving translational predictability to generate higher-value partnering opportunities.
• Expand geographic and therapeutic-area partnerships to convert platform discoveries into diverse clinical programs.
• Maintain capital efficiency through deal structuring that funds R&D while preserving upside via royalties and equity-linked returns.

PeptiDream Inc. (4587.T) - Vision Statement

• Drive platform-enabled innovation: scale PeptiDream's Peptide Discovery Platform (PDP) to generate high-quality preclinical candidates across therapeutic areas.
• Partner-centric growth: expand strategic alliances with global pharma to diversify risk and create multiple value-inflection points.
• Patient-first outcomes: prioritize programs with clear clinical pathways to improve morbidity, mortality, and quality of life.
• Long-term shareholder value: balance R&D intensity with disciplined capital allocation and transparent reporting.

• Expertise - Humility and continuous learning
  • PeptiDream fosters technical mastery and cross-disciplinary collaboration; the company invests in internal training and external scientific partnerships to maintain cutting-edge competencies.
• Passion - Patient-centric perseverance and creativity
  • Employees are encouraged to pursue bold ideas and remain resilient through iterative discovery cycles focused on patient impact.
• Integrity - Ownership, transparency, and respect
  • Decisions emphasize ethical conduct, clear accountability, and constructive learning from setbacks.

• Performance review metrics that include scientific outputs (e.g., discovery candidates generated), partnership milestones achieved, and demonstrated learning behaviors.
• Resource allocation that prioritizes platform R&D alongside diversified partnered programs to spread technical and regulatory risk.
• Cross-functional teams and governance forums that embed integrity-documented decision logs, post-mortems, and transparent partner reporting.

• Expertise: multi-disciplinary discovery teams combine chemistry, biology, and informatics to increase hit-to-lead efficiency and reduce attrition.
• Passion: patient-focused program prioritization leads to pipeline choices emphasizing indications with clear unmet need and feasible regulatory pathways.
• Integrity: transparent milestone reporting to partners and investors, and systematic post-program reviews to capture lessons learned.